Aeglea BioTherapeutics Inc

NASDAQ:AGLE   3:59:27 PM EDT
7.43
+0.03 (+0.40%)
Products

Aeglea Biotherapeutics And Immedica Announce Commercialization Agreement

Published: 03/22/2021 12:48 GMT
Aeglea BioTherapeutics Inc (AGLE) - Aeglea Biotherapeutics and Immedica Announce Commercialization Agreement for Pegzilarginase for the Treatment of Arginase 1 Deficiency in Europe and Middle East.
Aeglea Bio Therapeutics - Co Receives $21.5 Million Upfront With Up to About $130 Million in Milestone Payments and Royalties in Mid-twenties.
Aeglea Bio Therapeutics Inc - Immedica Obtains Exclusive Commercialization Rights in Europe and Several Middle Eastern Countries.
Aeglea Bio Therapeutics - Co Will Continue to Be Responsible for Certain Clinical Development Activities and Manufacturing of Pegzilarginase.
Aeglea Bio Therapeutics - Retains Commercialization Rights of Pegzilarginase in U.S. and Rest of World.